Does a fast nuclear magnetic resonance spectroscopy- And X-ray crystallography hybrid approach provide reliable structural information of ligand-protein complexes? A case study of metalloproteinases

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1712-1722

  Isaksson, Johan ^a   Nystrom, Susanne ^a   Derbyshire, Dean ^a   Wallberg, Hans ^a   Agback, Tatiana ^a   Kovacs, Helena ^b   Bertini, Ivano ^c   Giachetti, Andrea ^c,d   Luchinat, Claudio ^c  

^a MEDIVIR AB   (Sweden)

^b BRUKER BIOSPIN AG   (Switzerland)

^c UNIVERSITY OF FLORENCE   (Italy)

^d ProtEra Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CGS 27023A; METALLOPROTEINASE;

ARTICLE; CRYSTAL STRUCTURE; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; METALLOPROTEASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 64349111295     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801388q     Document Type: Article

References (49)

1. Brunger, A. T. X-ray crystallography and NMR reveal complementary views of structure and dynamics. Nat. Struct. Biol. 1997, 4 (Suppl), 862-865.
2. Medek, A.; Olejniczak, E. T.; Meadows, R. P.; Fesik, S. W. J. Biomol. NMR 2000, 18, 229.
3. Bertini, I.; Calderone, V.; Fragai, M.; Giachetti, A.; Loconte, M.; Luchinat, C.; Maletta, M.; Nativi, C.; Yeo, K. J. Exploring the Subtleties of Drug-Receptor Interactions: The Case of Matrix Metalloproteinases. J. Am. Chem. Soc. 2007, 129, 2466-2475.
4. Trzesniak, D.; Glattli, A.; Jaun, B.; Van Gunsteren, W. F. Interpreting NMR Data for beta-Peptides Using Molecular Dynamics Simulations. J. Am. Chem. Soc. 2005, 127, 14320-14329.
5. Religa, T. L. Comparison of multiple crystal structures with NMR data for engrailed homeodomain. J. Biomol. NMR 2008, 40, 189-202.
6. Trzesniak, D.; Van Gunsteren, W. F. Catalytic mechanism of cyclo-philin as observed in molecular dynamics simulations: pathway prediction and reconcilation of X-ray crystallographic and NMR solution data. Protein Sci. 2006, 15, 2544-2551.
7. Bonvin, A. M.; Brunger, A. T. Do NOE distance contain enough information to assess the relative populations of multiconformer structures. J. Biomol. NMR 1996, 7, 72-76.
8. van Gunsteren, W. F.; Dolenc, J.; Mark, A. E. Molecular simulation as an aid to experimentalists. Curr. Opin. Struct. Biol. 2008, 18, 149-153.
9. Vallurupalli, P.; Hansen, F.; Kay, L. E. Probing Structure in Invisible Protein States with Anisotropic NMR Chemical Shifts. J. Am. Chem. Soc. 2008, 130, 2734-2735.
10. Vallurupalli, P.; Hansen, F.; Kay, L. E. Structures of invisible, excited protein states by relaxation dispersion NMR spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11766-11771.
11. Hansen, F.; Vallurupalli, P.; Lundstrom, P.; Neudecker, P.; Kay, L. E. Probing Chemical Shifts of Invisible States of Proteins with Relaxation Dispersion NMR Spectroscopy: How Well Can We Do? J. Am. Chem. Soc. 2008, 130, 2667-2675.
12. Lindorff-Larsen, K.; Best, R. B.; DePristo, M. A.; Dobson, C. M.; Vendruscolo, M. Simultaneous determination of protein structure and dynamics. Nature 2005, 433, 128-132.
13. Lange, O. F.; Lakomek, N. A.; Farès, C.; Schroder, G. F.; Walter, K. F.; Becker, S.; Meiler, J.; Grubmüller, H.; Griesinger, C.; de Groot, B. L. Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 2008,13 (5882), 1429-1430.
14. Zagrovic, B.; Jayachandran, G.; Millett, I. S.; Doniach, S.; Pande, V. S. How Large is an alpha-Helix? Studies of the Radii of Gyration of Helical Peptides by Small-Angle X-ray Scattering and Molecular Dynamics. J. Mol. Biol. 2005, 353, 232-241.
15. Lau, A. Y.; Roux, B. The Free Energy Landscapes Governing Conformational Changes in a Glutamate Receptor Ligand-Binding Domain. Structure 2007, 15, 1203-1214.
16. Bertini, I.; Fragai, M.; Giachetti, A.; Luchinat, C.; Maletta, M.; Parigi, G.; Yeo, K. J. Combining in Silico Tools and NMR Data to Validate Protein- Ligand Structural Models: Application to Matrix Metalloproteinases. J. Med. Chem. 2005, 48, 7544-7559.
17. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.-I.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor that Blocks Cartilage Degradation in Rabbits. J. Med. Chem. 1997, 40 (16), 2525-2532.
18. Mecham, R. P.; Broekelmann, T. J.; Fliszar, C. J.; Shapiro, S. D.; Welgus, H. G; Senior, R. M. Elastin degradation by matrix metallo-proteinases. Cleavage site specificity and mechanisms of elastolysis. J. Biol. Chem. 1997, 272, 18071-18076.
19. Belaaouaj, A.; Shipley, J. M.; Kobayashi, D. K.; Zimonjic, D. B.; Popescu, N.; Silverman, G. A.; Shapiro, S. D. Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J. Biol. Chem. 1995, 270, 14568-14575.
20. Vaalamo, M.; Karjalainen-Lindsberg, M. L.; Puolakkainen, P.; Kere, J.; Saarialho-Kere, U. Distinct expression profies of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am. J. Pathol. 1998, 152, 1005-1014.
21. Hautamaki, R. D.; Kobayashi, D. K.; Senior, R. M.; Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277, 2002-2004.
22. Shipley, J. M.; Wesselschmidt, R. L.; Kobayashi, D. K.; Ley, T. J.; Shapiro, S. D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 942-946.
23. Rosenberg, G. A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 2002, 8, 586-595.
24. Snider, G. L. Understanding inflammation in chronic obstructive pulmonary disease: the process begins. Am. J. Respir. Crit. Care Med 2003, 167, 1045-1046.
25. Liu, M.; Sun, H.; Wang, X.; Koike, T.; Mishima, H.; Ikeda, K.; Watanabe, T.; Ochiai, N.; Fan, J. Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. Arhritis Rheum. 2004, 50, 3112-3117.
26. Banci, L.; Bertini, I.; Ciulli, A.; Fragai, M.; Luchinat, C.; Terni, B. Expression and high yield production of the catalytic domain of matrix metalloproteinase 12 and of an active mutant with increased solubility. J. Mol. Catal. A: Chem 2003, 204-205, 401-408.
27. Lang, R.; Kocourek, A.; Braun, M.; Tschesche, H.; Huber, R.; Bode, W.; Maskos, K. Substrate specificity determinants of human macrophage elastase (MMP-12) based in the 1.1 Å crystal structure. J. Mol. Biol. 2001, 312, 731-742.
28. 15N labeling. J. Biomol. NMR 1996, 8, 417-428.
29. Morales, R.; Perrier, S.; Florent, J. M.; Beltra, J.; Dufour, S.; De Mendez, I.; Manceau, P.; Tertre, A.; Moreau, F.; Compere, D.; Dublanchet, A. C.; O'Gara, M. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J. Mol. Biol. 2004, 341, 1063-1076.
30. McPherson, A., Preparation and Analysis of Protein Crystals; John Wiley: New York, 1982.
31. Keller, R. The Computer Aided Resonance Assignment Tutorial, 1st ed.; Cantina Verlag: Goldau, Switzerland, 2004.
32. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
33. Gasteiger, J.; Marsili, M. Iterative Partial Equilization of Orbital Electronegativity-A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
34. Kleywegt, G. J.; Jones, T. A. Methods Enzymol. 1997, 277, 208-230.
35. Guha, R.; Howard, M. T.; Hutchinson, G. R.; Murray-Rust, P.; Rzepa, H.; Steinbeck, C.; Wegner, J. K.; Willighagen, E. The Blue Obelisk-Interoperability in Chemical Informatics. J. Chem. Inf. Model. 2006, 46 (3), 991-998.
36. MacKerell, A. D., Jr.; Wiorkiwicz-Kuczera, J.; Karplus, M. An All-Atom Empirical Energy Function for the Simulation of Nucleic Acids. J. Am. Chem. Soc. 1995, 117, 11946-11975.
37. Best, R. B.; Lindorff-Larsen, K.; DePristo, M. A.; Vendruscolo, M. Relation between native ensembles and experimental structures of proteins. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (29), 10901-10906.
38. Nar, H.; Werle, K.; Bauer, M. M. T.; Dollinger, H.; Jung, B. Crystal Structure of Human Macrophage Elastase (MMP-12) in Complex with a Hydroxamic Acid Inhibitor. J. Mol. Biol. 2001, 312, 743-751.
39. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryfstalloogr. Sect. A: Found Crystallogr. 1991, 47, 110-119.
40. Gonella, N. C.; Li, Y.-C.; Zhang, X.; Paris, C. G. Bioactive Conformation of a Potent Stromelysin Inhibitor Determined by X-Nucleus Filtered and Multidimensional NMR Spectroscopy. Bioorg. Med. Chem. 1997, 5 (12), 2193-2201.
41. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Below, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
42. Schwieters, C. D.; Kuszewski, J. J.; Tjandra, N.; Clore, G. M. The Xplor-NIH NMR Molecular Structure Determination Package. J. Magn. Reson. 2003, 160, 66-74.
43. Bertini, I.; Calderone, V.; Cosenza, M.; Fragai, M.; Lee, Y.-M.; Luchinat, C.; Mangani, S.; Terni, B.; Turano, P. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (15), 5334-5339.
44. Rowsell, S.; Hawtin, P.; Minshull, C. A.; Jepson, H.; Brockbank, S. M.; Barratt, D. G.; Slater, A. M.; McPheat, W. L.; Waterson, D.; Henney, A. M.; Pauptit, R. A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 2002, 319, 173-181.
45. Tochowicz, A.; Maskos, K.; Huber, R.; Oltenfreiter, R.; Dive, V.; Yiotakis, A.; Zanda, M.; Bode, W.; Goettig, P. Crystal Structures of MMP-9 Complexes with Five Inhibitors: Contribution of the Flexible Arg424 Side Chain to Selectivity. J. Mol. Biol. 2007, 371, 989-1006.
46. Blagg, J. A.; Noe, M. C.; Wolf-Gouveia, L. A.; Reiter, L. A.; Laird, E. R.; Chang, S. P.; Danley, D. E.; Downs, J. T.; Elliott, N. C.; Eskra, J. D.; Griffiths, R. J.; Hardink, J. R.; Haugeto, A. I.; Jones, C. S.; Liras, J. L.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Pandit, J.; Robinson, R. P.; Subramanyam, C.; Vaughn-Bowser, M. L.; Yocum, S. A. Potent pyrimidinetrione- based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg. Med. Chem. Lett. 2005, 15, 1807-1810.
47. Wu, J.; Rush, T. S., III; Hotchandani, R.; Du, X.; Geck, M.; Collins, E.; Xu, Z. B.; Skotnicki, J.; Levin, J. I. Identification of potent and selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4105-4109.
48. Johnson, A. R.; Pavlovsky, A. G.; Ortwine, D. F.; Prior, F.; Man, C. F.; Bornemeier, D. A.; Banotai, C. A.; Mueller, W. T.; McConnell, P.; Yan, C.; Baragi, V.; Lesch, C.; Roark, W. H.; Wilson, M.; Datta, K.; Guzman, R.; Han, H. K.; Dyer, R. D. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 2007, 282, 27781-27791.
49. Li, J.; Brick, P.; O'Hare, M. C.; Skarzynski, T.; Lloyd, L. F.; Curry, V. A.; Clark, I. M.; Bigg, H. F.; Hazleman, B. L.; Cawston, T. E. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. Structure 1995, 3, 541-549.